Filing Flows › Neuraxis (NRXS) › R&D spending
Neuraxis (NRXS) R&D spending by quarter
Neuraxis' R&D spending was $274K in Q2 2026 (second quarter 2026), +176% from Q1 2026. Over the last 7 quarters it ranged from $58K (Q2 2025) to $274K (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $274K | +176% | +370% |
| Q1 2026 | $100K | -32% | +64% |
| Q4 2025 | $146K | +12% | +98% |
| Q3 2025 | $131K | +124% | — |
| Q2 2025 | $58K | -4% | — |
| Q1 2025 | $61K | -18% | — |
| Q4 2024 | $74K | — | — |
Q2 2026 at a glance
Neuraxis, Q2 2026: revenue $1.9M (+116% year over year), operating margin -110.2%, net loss $2.1M, operating cash flow −$1.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Neuraxis' R&D spending?
Neuraxis' R&D spending was $274K in Q2 2026 (second quarter 2026), +176% from Q1 2026.
How has Neuraxis' R&D spending changed?
Over the last 7 quarters it ranged from $58K (Q2 2025) to $274K (Q2 2026).